In the present study, we have showed that STF inhibition of IRE1α is capable of reversing existing insulin resistance and obesity and therefore validate the notion of targeting IRE1α inhibition as a potential therapeutic target for the treatment of obesity and related metabolic disorders. Here, ERN1 is linked to obesity disorder.